Regeneron Pharmaceuticals (REGN) Long-Term Debt Repayments (2013 - 2017)

Regeneron Pharmaceuticals' Long-Term Debt Repayments history runs 5 years deep, the most recent figure standing at $37.1 million for Q4 2017.

• On a quarterly basis, Long-Term Debt Repayments rose 14730.0% year-over-year to $37.1 million in Q4 2017; TTM through Sep 2018 was $37.1 million, a 83.77% increase from a year earlier, with the FY2017 full-year figure at $57.0 million, up 341.86% from the prior year.
• Long-Term Debt Repayments advanced to $37.1 million in Q4 2017 per REGN's latest filing, from -$37.1 million in the prior quarter.
• Across five years, Long-Term Debt Repayments topped out at $140.1 million in Q4 2015 and bottomed at -$117.6 million in Q3 2015.
• The 5-year median for Long-Term Debt Repayments is $6.7 million (2015), against an average of $17.9 million.
• Across the five-year window, Long-Term Debt Repayments slumped 2974.11% in 2014 and surged 25804.68% in 2015, its largest moves.
• Year by year, Long-Term Debt Repayments stood at -$2.0 million in 2013, then slumped by 2974.11% to -$62.2 million in 2014, then jumped by 325.11% to $140.1 million in 2015, then plunged by 99.82% to $250000.0 in 2016, then jumped by 14730.0% to $37.1 million in 2017.
• Per Business Quant, the three latest REGN Long-Term Debt Repayments figures stand at $37.1 million (Q4 2017), -$37.1 million (Q2 2017), and $57.0 million (Q1 2017).